Article

The CY2027 Star Ratings reset: What Medicare advantage plans must rethink now

Dianna Coles Lee-Sam
Director – Platform Engineering, CitiusTech

27-Apr-2026

Introduction: A strategic inflection point for Medicare advantage

The CY2027 Medicare Advantage and Part D Final Rule issued by the Centers for Medicare & Medicaid Services (CMS) marks a decisive reset in how quality, performance, and financial incentives are structured for health plans. The rule signals a clear shift away from administrative compliance and toward outcomes-based performance, with direct implications for Star Ratings, revenue stability, and long-term competitiveness.

At its core, the CY2027 rule simplifies the Star Ratings program, reduces the total number of measures, and increases the relative importance of the measures that remain. While certain administrative burdens are reduced, the overall impact is a more demanding quality environment where each measure carries greater financial and reputational stakes.

A streamlined Star Ratings program with higher stakes

One of the most significant changes under the CY2027 Final Rule is the restructuring of the Star Ratings program. CMS finalized the removal of multiple measures, particularly those that were administrative in nature or widely considered “topped-out,” where most plans already perform at similarly high levels.

By narrowing the measure set, CMS aims to make Star Ratings more meaningful and reflective of real performance differences across plans. However, this consolidation also increases exposure: with fewer measures contributing to overall ratings, performance variability in any single measure will have a much larger impact on a plan’s final Star Rating and associated quality bonus payments.

Importantly, while CMS chose not to move forward with the proposed Health Equity Index reward structure, the existing reward factor methodology remains in place. This limits immediate financial incentives tied specifically to equity performance, but it does not reduce CMS’s broader expectation that health plans actively address disparities in care delivery and outcomes.

Greater emphasis on outcomes and member experience

The CY2027 Final Rule reinforces CMS’s ongoing shift toward outcomes-based measurement. Measures tied to clinical effectiveness, medication adherence, and member experience – particularly those captured through HEDIS and CAHPS – now play a more central role in determining Star Ratings performance.

For Medicare Advantage organizations, this represents a fundamental change in how success is achieved. Performance will depend less on process adherence and reporting completeness, and more on demonstrable improvements in member health outcomes and satisfaction. To remain competitive, plans will need to strengthen care management programs, enhance provider collaboration, and deploy targeted interventions that directly influence clinical results and patient experience.

This shift rewards plans that can translate strategy into measurable improvements at the member level, rather than those that rely primarily on operational optimization or administrative excellence.

Financial pressure and margin sensitivity intensify

From a financial standpoint, the CY2027 rule introduces additional pressure for Medicare Advantage organizations. With only modest payment increases projected and continued changes to risk adjustment and coding normalization, many plans are expected to experience margin compression.

In this environment, Star Ratings performance becomes even more critical as a driver of quality bonus payments and overall revenue stability. At the same time, changes stemming from the Inflation Reduction Act continue to reshape the Part D benefit, altering cost-sharing structures and redistributing financial responsibility among plans, manufacturers, and the federal government.

Together, these dynamics add complexity to forecasting, bid development, and financial planning – particularly for plans with large prescription drug portfolios and diverse member populations.

CMS finalizes removal of 11 Star Ratings measures

As part of its effort to reduce administrative burden and sharpen the focus on meaningful differentiation, CMS finalized the removal of 11 Star Ratings measures under the CY2027 Final Rule. These measures largely fall into administrative, complaint, and operational categories and include:

Adult BMI Assessment
Appeals Auto-Forward
Call Center – Foreign Language Interpreter and TTY Availability
Complaints About the Health Plan
Members Choosing to Leave the Plan
Appeals Timeliness
Reviewing Appeals Decisions
Beneficiary Access and Performance Problems (Part D)
Call Center – Hold Time
Drug Plan Quality Improvement (Part D)
Medication Therapy Management (MTM) Program Completion Rate

Historically, many of these measures showed limited variation across plans, reducing their usefulness as quality differentiators. Their removal increases the relative weight and impact of remaining measures, particularly those related to clinical care, medication adherence, and patient experience – raising the performance bar across these domains.

Operational simplification, but not reduced accountability

Operationally, the CY2027 Final Rule includes simplifications across certain enrollment, marketing oversight, and administrative reporting requirements. While these changes help reduce regulatory burden, they do not lessen the need for strong internal governance.

In fact, as some external reporting requirements decrease, health plans assume greater responsibility for internally monitoring performance, managing delegated vendors, and ensuring data accuracy across systems. The ability to integrate, analyze, and act on data in near real time becomes increasingly critical – especially as CMS continues its transition toward digital quality measurement.

Health equity: Still a strategic imperative

Although CMS did not implement the Health Equity Index reward structure at this time, equity remains a strategic and regulatory priority. The absence of an explicit new financial incentive may prompt some plans to reassess their approach, but successful organizations will continue to embed equity within broader clinical and operational strategies rather than treating it as a standalone initiative.

This includes improving access to care, addressing social determinants of health, and ensuring that interventions effectively reach high-risk and underserved populations in a measurable and sustainable way.

A more focused, but more demanding performance environment

Taken together, the CY2027 changes create a Star Ratings environment that is simpler in structure but more demanding in execution. With fewer measures and greater emphasis on outcomes, variability in Star Ratings performance is likely to increase.

Plans that fail to adapt risk declines in ratings and revenue, while those that realign their strategies with CMS priorities – focusing on outcomes, member experience, and data-driven execution – stand to gain a competitive advantage.

How Payers should respond

To prepare for the CY2027 reset, Payers should begin with a comprehensive impact assessment to understand how measure removals and weighting changes affect current performance and revenue projections. This should be followed by a realignment of quality strategies toward the highest-impact clinical and experience measures, alongside enhancements to provider engagement and incentive models.

Over the longer term, sustained investment in data infrastructure, interoperability, and digital quality capabilities will be essential to succeed in an increasingly outcomes-driven environment.

Conclusion: Moving from compliance to true performance improvement

The CY2027 Medicare Advantage Final Rule signals a continued evolution toward value-based care. By prioritizing meaningful health outcomes, simplifying measurement, and restructuring incentives, CMS is encouraging health plans to move beyond compliance and toward true performance improvement.

Organizations that recognize this shift early and act decisively will be best positioned to improve Star Ratings, strengthen financial performance, and deliver better outcomes for members in the next phase of Medicare Advantage.